Key result
Aliskiren/valsartan/hydrochlorothiazide produced significantly greater reductions in systolic/diastolic blood pressure (22/16 mm Hg) compared to hydrochlorothiazide alone (6/6 mm Hg) at 8 weeks.
Why the study?
Does aliskiren/valsartan/HCTZ combination therapy improve blood pressure reduction in hypertensive patients not adequately responsive to HCTZ alone?
Population
641 hypertensive patients not adequately responsive to hydrochlorothiazide monotherapy
Comparison
Aliskiren/valsartan/HCTZ combination therapy for… vs Aliskiren/HCTZ, valsartan/HCTZ, or HCTZ alone…
Design
Other
Follow-up
8 weeks
Authors
Loading...
Supports triple aliskiren/valsartan/HCTZ over HCTZ monotherapy in uncontrolled hypertension; extends RCT evidence for combination regimens in resistant hypertension.
RCT (n=641)
Does aliskiren/valsartan/HCTZ combination therapy improve blood pressure reduction in hypertensive patients not adequately responsive to HCTZ alone?
Absolute Event Rate: 16% vs 6%
Triple combination therapy with aliskiren, valsartan, and HCTZ provides superior blood pressure reduction compared to dual therapy or monotherapy in patients unresponsive to HCTZ alone.
Geiger et al. (2009) conducted an RCT in Hypertension not adequately responsive to hydrochlorothiazide alone (n=641). Aliskiren/valsartan/hydrochlorothiazide vs. Aliskiren/hydrochlorothiazide, valsartan/hydrochlorothiazide, or hydrochlorothiazide alone was evaluated on Change in diastolic blood pressure from baseline to week 8 end point. Aliskiren/valsartan/hydrochlorothiazide produced significantly greater reductions in systolic/diastolic blood pressure (22/16 mm Hg) compared to hydrochlorothiazide alone (6/6 mm Hg) at 8 weeks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: